LBG
ALXN

Lloyds Banking Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Lloyds Banking Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-3,271
Closed -$542K – 434
2014
Q3 		$542K Sell
3,271
-382
-10% -$62.7K 0.15% 169
2014
Q2 		$570K Sell
3,653
-44,834
-92% -$7.08M 0.14% 174
2014
Q1 		$7.38M Buy
48,487
+5,591
+13% +$889K 0.07% 245
2013
Q4 		$5.71M Buy
42,896
+3,139
+8% +$377K 0.05% 280
2013
Q3 		$4.62M Buy
39,757
+2,746
+7% +$301K 0.05% 281
2013
Q2 		$3.41M Buy
+37,011
New +$3.57M 0.04% 315

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Lloyds Banking Group's ALXN Position: Q4 2014 in Review

Lloyds Banking Group sold out of Alexion Pharmaceuticals (ALXN) in Q4 2014, closing a stake of 3,271 shares — an estimated $542K sold.

Lloyds Banking Group first reported a position in ALXN in Q2 2013 and held it in 6 quarters. The position peaked at $7.38M in Q1 2014. 579 funds tracked by Wall St. Rank hold ALXN as of Q4 2014.

  • Lloyds Banking Group reported no remaining Alexion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Lloyds Banking Group sold 3,271 Alexion Pharmaceuticals shares in Q4 2014, an estimated $542K.
  • Lloyds Banking Group first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 6 quarters.
  • Lloyds Banking Group's Alexion Pharmaceuticals position peaked at $7.38M in Q1 2014.
  • 579 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2014.

Based on Lloyds Banking Group's 13F filing for Q4 2014, filed 12 Feb 2015.